Nuvectis Pharma Earnings Estimate
| NVCT Stock | USD 6.74 0.37 5.81% |
Nuvectis |
Nuvectis Pharma Earnings Estimation Breakdown
The calculation of Nuvectis Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Nuvectis Pharma is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Nuvectis Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Nuvectis Pharma Earnings Projection Consensus
Suppose the current estimates of Nuvectis Pharma's value are higher than the current market price of the Nuvectis Pharma stock. In this case, investors may conclude that Nuvectis Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Nuvectis Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 3 | 75.54% | -0.24 | 0.0 | -1.16 |
Nuvectis Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of Nuvectis Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Nuvectis Pharma predict the company's earnings will be in the future. The higher the earnings per share of Nuvectis Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Nuvectis Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Nuvectis Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Nuvectis Pharma should always be considered in relation to other companies to make a more educated investment decision.Nuvectis Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Nuvectis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.2533 | -0.24 | 0.0133 | 5 | ||
2024-08-07 | 2024-06-30 | -0.26 | -0.262 | -0.002 | 0 | ||
2024-05-07 | 2024-03-31 | -0.4 | -0.25 | 0.15 | 37 | ||
2024-03-05 | 2023-12-31 | -0.36 | -0.41 | -0.05 | 13 | ||
2023-11-08 | 2023-09-30 | -0.34 | -0.37 | -0.03 | 8 | ||
2023-08-09 | 2023-06-30 | -0.29 | -0.38 | -0.09 | 31 | ||
2023-05-10 | 2023-03-31 | -0.44 | -0.27 | 0.17 | 38 | ||
2023-03-07 | 2022-12-31 | -0.38 | -0.49 | -0.11 | 28 | ||
2022-11-08 | 2022-09-30 | -0.27 | -0.42 | -0.15 | 55 | ||
2022-08-05 | 2022-06-30 | -0.23 | -0.28 | -0.05 | 21 | ||
2022-05-10 | 2022-03-31 | -0.23 | -0.32 | -0.09 | 39 | ||
2022-03-22 | 2021-12-31 | -0.85 | -0.48 | 0.37 | 43 | ||
2021-10-21 | 2021-09-30 | 0 | -24.43 | -24.43 | 0 |
About Nuvectis Pharma Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Nuvectis Pharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Nuvectis Pharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Nuvectis Pharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -48.8 M | -46.4 M | |
| Retained Earnings Total Equity | -28.8 M | -30.2 M | |
| Earnings Yield | (0.20) | (0.21) | |
| Price Earnings Ratio | (5.25) | (5.51) | |
| Price Earnings To Growth Ratio | 1.55 | 1.63 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.